60 Degrees Pharmaceuticals Releases Tafenoquine Babesiosis Interim Data

60 Degrees Pharmaceuticals is set to disclose interim analysis results from its hospitalized babesiosis study (NCT06207370) on October 6, 2026, a readout that could initiate regulatory submission planning and manufacturing scale-up conversations for a tick-borne indication with no currently FDA-approved therapy.

The data release coincides with a Key Opinion Leader webinar featuring Dr. Peter Krause of Yale School of Public Health and Dr. Edouard Vannier of Tufts Medical Center, both recognized clinical researchers in Babesia microti infection. The session will cover the clinical burden of persistent babesiosis in immunocompromised patients, limitations of existing treatment guidelines, and the mechanistic basis for tafenoquine combination therapy.

Tafenoquine is currently approved by the FDA for malaria prophylaxis under the brand name ARAKODA, a 2018 approval that established the compound's regulatory precedent in the U.S. Any label expansion into babesiosis would represent a distinct indication requiring a separate regulatory pathway, with associated process validation and supply chain considerations for a small-cap sponsor.

For drug development and regulatory affairs teams tracking unmet-need indications, the interim readout carries weight beyond the clinical result itself. Babesiosis, particularly in relapsing and treatment-refractory cases, has no approved pharmacological option, a gap that positions a positive interim signal as a potential trigger for accelerated development timelines and early FDA engagement. Dr. Krause led the original trial that established atovaquone/azithromycin as standard-of-care roughly 25 years ago; his participation lends clinical credibility to the program's evidentiary framing.

The live webinar is scheduled for 11:00 a.m. ET on October 6, with a question-and-answer session to follow the formal presentation.

The interim analysis outcome will determine whether 60 Degrees advances toward a full dataset and, by extension, whether a regulatory submission strategy for babesiosis moves from contingency planning into active development.

Source: 60 Degrees Pharmaceuticals via GlobeNewswire, October 1, 2026. KOL webinar scheduled for October 6, 2026, 11:00 a.m. ET.